An observation for adverse effect of Total glucosides of paeony in patients with rheumatic diseases and dermatopathy: a multicenter, non-interventional, registration study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018652

Enrollment

Unknown

Registered

2018-10-02

Start date

2018-04-17

Completion date

Unknown

Last updated

2018-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic diseases and dermatopathy

Interventions

Case series:Total glucosides of paeony (TGP)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Patients identified to received TGP monotherapy or combination therapy in department of rheumatology and immunology and Department of Dermatology; (2) Patients agree and sign written informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with advanced, severe or life-threatening illness, any medical or mental condition, or other causes judged by the researchers not suitable for this study; (2) Patients unable to sign written informed consent form.

Design outcomes

Primary

Measure	Time frame
Incidence of adverse reactions during 1 month of medication;	—

Secondary

Measure	Time frame
Adverse events during 1 months;Adverse reactions during 1 month of medication in patients with rheumatoid arthritis;Incidence of adverse reactions during 1 month of medication in patients with rheumatoid arthritis;Adverse events during 1 month of medication in patients with rheumatoid arthritis;	—

Countries

China

Contacts

Public ContactHUANG CIBO

Department of Rheumatology and Immunology

huangcibo1208@139.com+86 15810999904

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026